Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of the AbsnowTM II Absorbable Atrial Septal Defect Closure System for Atrial Septal Defect Closure Therapy
Sponsor: Lifetech Scientific (Shenzhen) Co., Ltd.
Summary
A prospective, multicenter, randomized controlled, non-inferiority clinical trial to evaluate the safety and efficacy of the AbsnowTM II absorbable atrial septal defect occluder system for atrial septal defect closure therapy. A parallel controlled comparison will be conducted using the Cera atrial septal defect occluder manufactured by the same company as the control device, to evaluate the safety and efficacy of the AbsnowTM II absorbable ASD occluder system in the treatment of ASD occlusion.
Official title: A Prospective, Multicenter, Randomized Controlled, Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of the AbsnowTM II Absorbable Atrial Septal Defect Occluder System for Atrial Septal Defect Closure Therapy
Key Details
Gender
All
Age Range
3 Years - Any
Study Type
INTERVENTIONAL
Enrollment
236
Start Date
2026-04
Completion Date
2031-12
Last Updated
2026-04-14
Healthy Volunteers
No
Conditions
Interventions
Absnow II Absorbable Atrial Septal Defect Occluder System
To evaluate the efficacy and safety of the AbsnowTM II absorbable atrial septal defect occluder system in the treatment of atrial septal defect.
Cera Atrial Septal Defect Occluder
The Cera atrial septal defect occluder produced by the same company serves as the control group.